Growth Hormone Axis Research
Preclinical investigation of compounds studied for GHRH receptor agonism, GH pulse modulation, somatotroph pharmacology, and IGF-1 axis regulation in rodent and primate models.
Research Overview
Growth hormone axis research examines the hypothalamic-pituitary somatotroph axis regulation, focusing on compounds that modulate GH secretion through GHRH receptor agonism, ghrelin receptor (GHSR-1a) agonism, or a combination of both mechanisms. The primary model systems are cannulated rat studies for serial GH sampling, GH-deficient dwarf rat models (lit/lit, dw/dw), aged Sprague-Dawley and C57BL/6 rodent cohorts with somatopause, and non-human primate pharmacokinetic studies. Tesamorelin was developed through Theratechnologies and characterized pharmacologically across a series of rat and primate studies documenting GHRH receptor binding, pituitary somatotroph activation, GH pulse augmentation, and downstream IGF-1 elevation. CJC-1295/Ipamorelin combined pharmacology has been characterized in Wistar rat serial sampling studies demonstrating synergistic GH release above individual compound effects. AOD-9604 (GH fragment 177-191) was characterized by Heffernan and Metabolic Pharmaceuticals researchers in DIO murine models for its GH-independent lipolytic activity.
Key Research Findings
Findings from preclinical in vitro and in vivo model systems. All summaries reference published research models.
GHRH Receptor Binding and GH Pulse Augmentation by Tesamorelin in Rats
Teramura and colleagues and Theratechnologies researchers documented that Tesamorelin bound the GHRH receptor with high affinity and produced dose-dependent increases in GH pulse amplitude in cannulated Sprague-Dawley rats, with peak GH concentrations 3 to 5-fold above vehicle controls following subcutaneous administration. Serial sampling studies confirmed that Tesamorelin augmented pulsatile GH without disrupting the normal pulsatile secretory pattern, consistent with preserved hypothalamic regulatory feedback in treated animals.
Synergistic GH Secretion by CJC-1295 and Ipamorelin Combination in Rat Studies
Pharmacodynamic studies in Wistar rats comparing CJC-1295 alone, Ipamorelin alone, and combined administration documented that the combination produced GH peak concentrations exceeding the sum of individual compound effects, confirming pharmacological synergy through complementary GHRH receptor and GHSR-1a signaling pathways. IGF-1 levels measured at 24 and 72 hours post-administration were also significantly elevated in the combination group compared to either single-compound group.
GH-Independent Lipolysis by AOD-9604 in DIO Murine Models
Heffernan et al. documented that AOD-9604 administration in C57BL/6 mice on 12-week high-fat diet produced selective reduction of epididymal and inguinal fat pad mass compared to vehicle-treated HFD controls, without elevating blood glucose, insulin, or IGF-1 levels, suggesting a mechanism of action distinct from canonical GH receptor-mediated metabolic effects. Beta-3 adrenergic receptor activation in adipocytes was proposed as one possible molecular entry point for AOD-9604 lipolytic activity in rodent adipose tissue preparations.
IGF-1 Elevation and Somatopause Reversal in Aged Murine Cohorts
Studies in aged Sprague-Dawley rats (18 to 24 months) treated with GHRH analog compounds documented restoration of IGF-1 levels toward those of young adult cohorts, with IGF-1 concentration increases of 40 to 80% above baseline in aged treated animals compared to age-matched vehicle controls. These findings in aging murine models establish that GH secretory capacity is maintained in aged somatotrophs and can be augmented by appropriate pharmacological stimulation with GHRH receptor agonists.
Compounds Studied in This Area
Research compounds with documented preclinical activity in this domain.
Broader Research Context
Growth hormone axis research benefits from highly standardized pharmacokinetic and pharmacodynamic model systems developed over decades of neuroendocrinology research. Serial blood sampling via indwelling catheters in rats provides detailed GH secretion profiles that enable pharmacodynamic parameter extraction, while IGF-1 ELISA provides a more tractable integrated biomarker for longer-term studies. The Tesamorelin pharmacology literature is the most rigorous in the GH secretagogue research peptide space, reflecting its pharmaceutical development history. CJC-1295 and Ipamorelin research is primarily documented in pharmaceutical company pharmacology reports and a more limited peer-reviewed literature compared to Tesamorelin.
Research Questions
Continue Your Research
Browse all research areas or explore the full Research Library for compound comparisons, study indexes, and use case guides.